WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
1 
 TITLE:                                         INFLUENZA VACCINATION IN PLASMA CELL 
DYSCRASIAS  
 
Coordinating  Center:    Winship Cancer Institute of Emory University   
 Winship PI :      Craig Hofmeister MD MPH  
 Laboratory i nvestigator : Madhav Dhodapkar MBBS  
 Sanofi : Fluzone  HD 
 Commercial  Agent:  Prevnar  13 (PCV 13)  
 Statistician:                           Yuan Liu, Ph.D Winship BBISR  
 Protocol / Date:  Initial / 7- May-2019  
 V 1.1 / 22- May-2019  
 V 1.2 / 13- Jul-2019 
 V 1.3 / 31- Oct-2019  
 V 1.31 / 13- Nov-2019  
 V 2.0 / 9- Mar-2020  
 V 2.1 / 7- Apr-2020  
 V 2.2 / 3- Jul-2020 
 V 2.3 / 20- Jul-2020 
 V 2.4 / 14- Sep-2020  
 CTCAE version : 5.0 
 Total consented patients:  175 total 
  50 patients (2019- 2020) of which 23 were evaluable  
  125 patients (2020- 2021)  
                 
Text color legend  
Blue text Instructions and detailed for correlative science for laboratory #1  
Blue text Instructions and detailed for correlative science for laboratory #2   
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
2 
 SCHEMA  
 
 
 
This is a phase IV randomized trial of 148 evaluable patients with a plasma cell disorder to be 
enrolled as early as possible in the influenza season  through 15- Dec.     
 Fluzone HD refers to TIV formulation for 2019- 2020 influenza season and QIV formulation 
for 2020- 2021 season.  
 After eligibility is confirmed, patients will be randomized 1:1 to either an experimental arm where each patient receives three injections of Fluzone HD and a control arm where each patient receives one injection of Fluzone HD.   
 All patients receive Prevnar at week 5  if they have not received either PCV13 or PPSV23 in 
that calendar year . 
   

WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
3 
 STANDARD OF CARE AND RESEARCH INTERVENTIONS  
 
 
  

WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
4 
  
Table of Contents  
 
1. PRIMARY HYPOTHESES, OBJECTIVES, AND ENDPOINTS  ........................................................................... 6 
2. EXPLORATORY SCIENTIFIC HYPOTHESES, OBJECTIVES, AND ENDPOINTS  ........................................ 6 
3. BACKGROUND  ........................................................................................................................................................... 6 
3.1 INFLUENZA OVERVIEW  ........................................................................................................................................................... 6 
3.2 INFLUENZA RISK IN ADULT CANCER PATIENTS  ................................................................................................................... 6 
3.3 INFLUENZA VACCINATION RESEARCH IN ALLOGENEIC TRANSPLANT PATIENTS  ............................................................ 7 
3.4 MULTIPLE MYELOMA  .............................................................................................................................................................. 7 
3.5 MYELOMA PATIENTS AND INFLUENZA  ................................................................................................................................. 8 
3.6 ASSESSMENT OF INFLUENZA VACCINATION RESPONSE  ..................................................................................................... 9 
3.7 STUDY RATIONALE  ............................................................................................................................................................... 10 
3.8 POTENTIAL RISKS AND BENEFITS  ...................................................................................................................................... 10 
4. PATIENT SELECTION ............................................................................................................................................. 11 
4.1 INCLUSION CRITERIA  ............................................................................................................................................................ 11 
4.2 EXCLUSION CRITERIA  .......................................................................................................................................................... 12 
5. REGISTRATION, ACCRUAL, AND EARLY TERMINATION  .......................................................................... 12 
5.1 ACCRUAL  ................................................................................................................................................................................ 12 
5.2 DURATION OF THERAPY  ...................................................................................................................................................... 13 
5.3 DURATION OF FOLLOW -UP ................................................................................................................................................. 14 
5.4 CRITERIA FOR REMOVAL FROM STUDY  .............................................................................................................................. 14 
5.5 EARLY STOPPING RULES  ...................................................................................................................................................... 14 
5.6 PREMATURE TERMINATION OR SUSPENSION OF THE STUDY  ......................................................................................... 14 
6. STUDY PROCEDURES & SCHEDULE .................................................................................................................. 14 
6.1 AGENT ADMINISTRATION  .................................................................................................................................................... 14 
6.2 DEFINITION OF DOSE -LIMITING TOXICITY  ........................................................................................................................ 15 
6.3 STANDARD OF CARE STUDY PROCEDURES  ........................................................................................................................ 15 
6.4 RESEARCH SPECIFIC PROCEDURES  ..................................................................................................................................... 15 
6.5 SCHEDULE OF EVENTS  ......................................................................................................................................................... 16 
6.6 DOSE LEVELS FOR PROTOCOL -SPECIFIC DRUGS  ............................................................................................................... 18 
6.7 DOSE INTERRUPTIONS  ......................................................................................................................................................... 18 
6.8 DOSE REDUCTION FOR OVERLAPPING TOXICITIES  ........................................................................................................... 18 
7. PHARMACEUTICAL INFORMATION  ................................................................................................................. 18 
7.1 FLUZONE HD ........................................................................................................................................................................ 18 
8. CORRELATIVE/SPECIAL STUDIES  .................................................................................................................... 24 
8.1 OBJECTIVE FOR LAB 1 - SANOFI  ......................................................................................................................................... 24 
8.2 OBJECTIVE FOR LAB 2 – DHODAPKAR LABORATORY  ...................................................................................................... 24 
9. RESPONSE  .................................................................................................................................................................  26 
10. STATISTICAL CONSIDERATIONS  ...................................................................................................................... 26 
10.1 STATISTICAL HYPOTHESES .................................................................................................................................................. 26 
10.2 ANALYSIS DATASETS  ............................................................................................................................................................ 26 
10.3 SAMPLE SIZE DETERMINATION  .......................................................................................................................................... 26 
10.4 STATISTICAL METHODS  ....................................................................................................................................................... 27 
10.5 MEASURE TO MINIMIZE BIAS  .............................................................................................................................................. 29 
11. ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS  ................................................................... 29 
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
5 
 11.1 IDENTIFICATION OF AES AND FOLLOW -UP ...................................................................................................................... 29 
11.2 EXPECTEDNESS  ..................................................................................................................................................................... 30 
11.3 ADVERSE EVENT CHARACTERISTICS  .................................................................................................................................. 30 
11.4 DEFINITION OF SERIOUS ADVERSE EVENT (SAE)  ........................................................................................................... 32 
11.5 DEFINITION OF UNANTICIPATED PROBLEMS (UP)  AND REPORTING REQUIREMENTS  .............................................. 33 
11.6 EXPEDITED ADVERSE EVENT REPORTING  ......................................................................................................................... 34 
11.7 MONITORING OF ADVERSE EVENTS AND PERIOD OF OBSERVATION  ............................................................................. 35 
11.8 SECOND AND SECONDARY MALIGNANCY  ........................................................................................................................... 35 
12. DATA REPORTING / REGULATORY REQUIREMENTS  ................................................................................ 35 
12.1 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA  ..................................................................................................... 35 
12.2 QUALITY ASSURANCE  ........................................................................................................................................................... 35 
12.3 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  ........................................................................................... 36 
12.4 STUDY RECORDS RETENTION  .............................................................................................................................................. 36 
12.5 WINSHIP DATA AND SAFETY MONITORING (DSMC)  ................................................................................................... 36 
12.6 PROTOCOL DEVIATIONS ....................................................................................................................................................... 37 
12.7 PUBLICATION AND DATA SHARING POLICY  ....................................................................................................................... 38 
12.8 AUDIT AND INSPECTION  ...................................................................................................................................................... 38 
13. ETHICS AND PROTECTION OF HUMAN SUBJECTS  ...................................................................................... 39 
13.1 ETHICAL STANDARD  ............................................................................................................................................................ 39 
13.2 INSTITUTIONAL REVIEW BOARD  ........................................................................................................................................ 39 
13.3 INFORMED CONSENT  ............................................................................................................................................................ 39 
13.4 PARTICIPANT AND DATA CONFIDENTIALITY  .................................................................................................................... 39 
13.5 RESEARCH USE OF STORED SAMPLES , SPECIMENS , OR DATA  ......................................................................................... 40 
REFERENCES  ...................................................................................................................................................................... 41 
APPENDIX A –  PERFORMANCE STATUS  ................................................................................................................... 44 
 
  
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
6 
 1. PRIMARY HYPOTHESES, OBJECTIVES, AND ENDPOINTS  
Clinical  
Hypothesis  Objective  Endpoint  
Continuous Fluzone 
HD throughout the flu 
season will improve  
hemagglutination 
inhibition (HAI > 40 )  
as measured at the end of the season compared 
to those patients that 
receive Fluzone HD 
once . 
 Demonstrate a n absolute 
25% increase in 
seroprotection, defined as 
HAI>40 against all strains, 
at week 21 in the 
experimental arm compared to the control arm.   
 HAI will be measured in all 
patients at baseline, week 5, and 
week 21  to calculate 
seroconversion at week 5 and 
seroprotection at week 21. 
 
Seroconversion: Pre -vaccination 
HAI<10 and a post -vaccination 
HAI>40 or a pre -vaccination 
HAI >10 and a ≥ 4- fold rise in 
post-vaccination HAI at week 5.  
 
   
The above measurables will appear in the results section of www.clinicaltrials.gov  at trial completion  
2. EXPLORATORY SCIENTIFIC HYPOTHESES, OBJECTIVES, AND ENDPOINTS  
Measurement of B & T -cell subsets and flu- specific responses  as a way of understanding 
immunosuppression in this patient population, correlating with influenza -like illness.  
3. BACKGROUND  
3.1 Influenza overview  
Influenza is an acute viral respiratory illness from three main types (A, B, and C), where type A is subcategorized based on viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA).  Primary influenza pneumonia is a rare but severe, complicated by otitis media and exacerbations of chronic 
respiratory conditions. Other complications include otitis media, exacerbations of 
chronic respiratory disease, myocarditis – often the concern is for influenza infection to ‘set the stage’ for a subsequent l ethal bacterial pneumonia.  Those at 
high- risk for complications include those with cardiopulmonary diseases, chronic 
care facility residents, and those over 65 years old.  Influenza vaccines contain antigens of the circulating influenza viruses and are intended to trigger antibody- mediated protection. Influenza A viruses undergo 
continual changes in the hemagglutinin (HA) and neuraminidase (NA) proteins, which necessitate an nual updates.   Current influenza vaccines are available as 
inactivated vaccine (IV), trivalent (TIV) or quadrivalent (QIV), usually A/H1N1, A/H3N2, and either one or two strains of B), and as a recombinant vaccine which may be TIV or QIV.  
3.2 Influenza risk in adult cancer patients  
There is no perfect sign of acquired immunosuppression in humans.  Neutropenia is often the consequence of chemotherapy that is watched most closely as it is associated with lethal bacterial infections especially when the absolute neu trophil 
count is less than 500/uL, and not surprisingly is associated with more influenza -
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
7 
 related complications than in the general population1. In two studies of different 
cancer patient populations, absolute lymphocyte count of less than 200/ uL was an 
independent predictor of progression to influenza -related pneumonia2. 
 
A review of vaccine immunogenicity among patients with both liquid and solid tumors demonstrated decreased seroconversion rate among cancer patients 
receiving chemotherapy (17% to 52%) compared to cancer patients not receiving 
chemotherapy (50% to 83%) and compared to healthy controls (67% to 100%)
3. 
 
People undergoing chemotherapy or those that have acquired profound immunosuppression seen after allogeneic stem cell transplantation are at increased 
risk of influenza -related complications
4,5. People at highest risk include those with 
impaired cell -mediated and antibody- mediated immunity, as reflected by a 
decrease in the number or function of T and B cells6. Influenza -related 
hospitalization rates are four times higher and mortality 10 times higher among 
people with cancer compared with the general population7,8. 
3.3 Influenza vaccination research in allogeneic transplant patients  
An open- label randomized trial included 78 patients at least a week before a 
planned allogeneic stem cell transplant9.  Odds ratio for all -cause mortality was 
1.05 (95% CI 0.4 to 2.77) among those vaccinated. Influenza -related mortality 
was similar as well between the groups (2/40 among vaccinated versus 2/38 among non- vaccinated). Documented influenza infection rate was similar in 
vaccinated and unvaccinated patients (3/40 vers us 4/38, respectively). GMTs at 30 
days post -vaccination among the vaccinated population were significantly higher 
for influenza A/H1N1 and influenza A/H3N2 strains (15 versus 10, p=  
0.03 and 30 versus 12.5, p< 0.001, respectively).  
 Another open- label randomized trial enrolled 73 adults after allogeneic HSCT, of 
which 35 were randomized to receive an adjuvanted influenza vaccine (Fluad) and the rest (38) randomized to a non- adjuvanted influenza vaccine (Influvac)
10. There 
were five cases (14%) of laboratory -confirmed influenza among patients receiving 
the adjuvanted vaccine compared to three cases (8%) in the non- adjuvanted 
vaccine group. Vaccine immunogenicity, reported as seroconversion rate, seroprotection rate, and GMTs, was not significantly higher in the adjuvanted vaccine group. This study was underpowered for conclusions regarding seroprotection or to identify differences in influenza -like illness between the 
groups. 
3.4 Multiple myeloma  
Multiple myeloma (MM) affects approximately 83,000 US citizens and over 50% of patients die within 5 years of diagnosis; more than half of patients older than 70 years with low albumin and high β2microglobulin die within a year of diagnosis
11,12. Of the 30,330 new cases estimated in 2016 in the U.S.13, MM is 
twice as common in African Americans as Caucasians, and genetic changes accumulate as plasma cells degenerate from monoclonal gammopathy of undetermined significance, through smoldering myeloma, to MM
14. MM is 
characterized by fractures, anemia, kidney failure, and hypercalcemia with a 
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
8 
 predisposition for bacterial infections from the inherent immunoparesis and 
varicella reactivation often aided by proteasome inhibition15. 
 Advances in high- dose chemotherapy and stem cell transplantation have improved 
overall survival and event -free disease periods in patients with MM, but relapses 
are inevitable
16,17 New therapeutic agents, such as new generation proteasome 
inhibitors (carfilzomib and ixazomib), immunomodulatory agents (lenalidomide 
and pomalidomide, the histone deacetylase inhibitor (HDACi) panobinostat, and 
monoclonal antibodies (elutuzumab and dara tumumab) have shown promising 
clinical benefit in patients with relapsed or refractory disease. Current treatments include regimens using proteasome inhibitors and/or immunomodulatory agents in 
combination with HDACi, alkylating agents, and monoclonal anti bodies. 
3.5 Myeloma patients and influenza  
In myeloma patients on treatment, there is a 20% likelihood of influenza -like 
illness18,19 with a 10- fold higher risk of viral URIs20 than the general population. 
Even patients with precancerous conditions such as monoclonal gammopathy of 
undetermined significance (MGUS)  and Smoldering Myeloma are at increased risk 
of bacterial and viral infections21. While only 3 -5% of these viral illnesses are 
influenza, the mortality is high in the immunosuppressed and post -influenza 
bacterial pneumonias have high morality. In addition myeloma and it’s precursor 
diseases provide a novel window to studying vaccinati on in a full spectrum of 
immunosuppression from non- cancerous low -risk MGUS to end- stage 
lymphopenic patients with relapsed multiple myeloma.  
Vaccine preventable illnesses have not been prevented in patients with myeloma 
due in part to lack of seroresponse with standard dosing algorithms. Based on available trial data restricted to myeloma patients, serologic protection (HAI titer ≥40) to all three influenza strains following trivalent influenza vaccine is achieved in less than 20% of myeloma patients in each trial
22-24.  There have been two trials 
investigating the benefit of booster vaccine in myeloma patients. In 2005 Ljungmen et al, studied 70 patients with hematologic malignancies (10 with myeloma and 4 with WM) and administered a booster dose 30 days following standard influenza vaccine booster and found no increase in serologic protection
25. More recently, in 
the past 2013 -2014 flu season, Hahn et al gave a standard dose influenza booster 
vaccine after 30 days to 25 myeloma patients and noted a doubling of serologic protection (HAI titer ≥40) from 14% to 33%
26. This suggests that there may be a 
role for booster vaccines in patients with hematologic malignancies, however there 
is obviously much room to improve. 
Prior studies by the Dhodapkar lab has evaluated serologic responses to repeat 
influenza vaccination in patients with plasma cell disorders. In the first 
SHIVERING trial, we analyzed a strategy of 2 vaccine Fluzone HD doses, which led to higher rates of se roprotection compared to historic controls
27. This was 
followed by a placebo- assisted randomized controlled study (SHIVERING -2 trial) 
comparing single dose versus 2- dose vaccination strategy. Th is trial28 provided first 
evidence that 2 -dose strategy leads to higher rates of seroprotection compared to 
current standard of annual influenza vaccination in these patients. At the end of the influenza season, the rates of sero- protection were 58% in the cohort wi th 2 
vaccines versus 33% for the cohort with standard vaccines (P<0.05). These results 
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
9 
 however need to be replicated in an independent study, before considering a change 
in standard practice.  These considerations have led to the design of the current trial, wherein we will evaluate 3 doses of the vaccine (versus standard influenza vaccinati on) in order to further extend the rates of seroprotection at the end of study 
and test the hypothesis that repeat dosing of influenza vaccines leads to superior sero-protection in patients with plasma cell disorders, compared to that achieved 
with current  standard vaccination strategy. If this trial replicates the findings with 
SHIVERING- 2 trial, we believe it should lead to a change in current clinical 
practice for influenza vaccination in patients with plasma cell disorders.  
3.6 Assessment of influenza vaccination response 
Influenza vaccines work by activating antigen- specific B -cells to proliferate and 
differentiate into plasmablasts that secrete protective antibodies and memory B 
cells that can rapidly proliferate and differentiate into plasmablasts  upon re -
encountering the immunizing antigen. Studies in healthy individuals demonstrated 
a transient plasmablast  response after vaccination peaking at around 7 days after 
vaccination at which point it makes up to 16% of all B -cell, and returning to 
baseline levels by day 14. Mem ory B -cell response, on the other hand, peaks  at 
14-28 days after vaccination followed by a slower rate of decline29-31. A subset of 
the plasmablasts  migrate to the bone marrow and become long- lived plasma cells 
secreting antigen -specific antibodies for protracted periods of time. Memory B -
cell and plasma cells provide a remarkably stable immunological memory that can persist over 50 years after vaccination in humans. Interestingly, plasma cells are not intrinsically long -lived and only a finite number of plasma cells  survive after 
an immune response irrespective of the number of plasma cells  generated, 
suggesting that plasma cells  require a specialized niche for survival
32. It remains 
unclear what factors direct the differentiation of activated, antigen -specific B -cells 
into either memory B -cells or plasmablasts  and plasma cells . Studies in mice 
suggested that the B -cell repertoire in the memory B -cell and the plasma cells  
compartments differ in terms of antigen -binding affinity and breadth33.  
 
Generation of immunological memory is the hallmark of adaptive immune 
responses. Clinically, this can be measured by determining seroprotection, defined 
as the percentage of subjects with a post -vaccination hemagglutination antibody 
inhibtion ( HAI) titer > 1:40; and seroconversion, the percentage of subjects with 
either a pre- vaccination H AI titer < 1:10 and a post -vaccination H AI titer > 1:40 
or a pre -vaccination H AI titer > 1:10 and a minimum four -fold rise in post -
vaccination H AI antibody titer by week 5.  
 
Clearance of viral infection and vaccine responses are dependent on cell 
mediated immunity. The most common  serologic measurement of antibody 
protection following influenza vaccine administration is an HAI titer of 40 or higher. However, this cutoff corresponds to an estimated 50% clinical benefit of 
preventing influenza infections, based on studies in young healthy adults
34,35. It is 
believed that cell- mediated immunity  declines with age, which may help explain 
why the elderly are more vulnerable to influenza infections. HAI titers have also 
been shown to be lower in the elderly compared to young adults. Based on 
studies showing increased serologic protection, Fluzone HD (TIV)  was FDA 
approved in 2009 for adults aged 65 and older , the QIV formulation in Nov -2019.  
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
10 
 3.7 Study rationale  
The challenge of decreasing influenza infection rate and severity in patients with 
hematologic malignancies  are manifold: first, influenza virus undergoes antigenic 
drift and antigenic shift allowing it to overcome pre -existing immunity; second, 
the fact that most vaccine -elicited neutralizing antibodies are directed against 
hypervariable epitopes of the HA protein, facilitating the emergence of antibody -
escape viral variants; third, the apparent short half -life of vaccine -mediated 
antibody titers in immunocompetent individuals; forth, the underlying immune suppressive state caused by the hematologic malignancy and worsened by the treatments that these patients need to receive; and fifth, the lack of high quality data looking at the response to influenza vaccination in patients with hematologic malignancy  at the different stages of their disease course. Therefore, more studies 
are needed to define the optimal timing of influenza vaccination in patients with hematologic malignancies  and to design an influenza vaccination strategy  that 
provides a long- lived antibody response  targeting  a conserved epitope in HA. 
 The National Comprehensive Cancer Network still recommends yearly 
vaccination using an inactivated influenza vaccine with the hope of achieving some protection and decrease the severity in the event of an infection. It is presumed that the higher incidence of  viral infections in patients with hematologic 
malignancies  is due to immune suppression associated with treatment and poor 
rates of seroconversion after vaccination. However, the exact mechanism of how this occurs is not well understood, limiting our a bility to design better preventive 
measures against influenza infection. T his study will measure immune responses 
to influenza vaccination in patients with plasma cell dyscrasias . 
3.8 Potential risks and benefits  
3.8.1 Potential risks  
1. Additional blood draws  - The physical risk of drawing blood is local 
pain and bruising at the site of venipuncture. Qualified phlebotomists 
or designee will draw blood samples. Care will be taken to obtain 
these specimens in a safe and hygienic manner. A small number of 
people experience lightheadedness or fainting. There is a slight risk of 
infection. To minimize these risks, attempts will be made to draw study blood samples at the same time as blood draws needed for routine 
clinical care are obtained. Repeated blood drawing may be associated 
with iron deficiency anemia.  
2. Extra influenza vaccination  - The side effects from inactivated 
influenza vaccine are generally mild. They include soreness at injection site (10- 64% of subjects) that lasts <2 days. When the 
vaccine is given, the subject may feel a slight pain and burning during the injection. Fever, malaise and myalgia can occur after vaccination 
with inactivated influenza vaccine. These reactions begin 6- 12 hours 
after vaccination and can persist for 1- 2 days.  Patients with a history 
of severe allergic reaction are not eligible to participate in this study. 
Very rarely, occurring in about 1 in 4 million people given a vaccination, there can be a serious allergic reaction to a vaccine. 
These reactions can manifest as skin rash (hives), angioedema, 
bronchospasm, tachycardia, or hypotension. If these reactions occur, 
they can usually be stopped by the administration of emergency 
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
11 
 medications by the study personnel.   It is not known whether 
additional influenza risk will increase the risk of Guillain- Barre 
syndrome (GBS), estimated at 2.84 per million doses.  
3. Data security - Subjects will be asked to provide personal health 
information (PHI). All attempts will be made to keep this PHI 
confidential within the limits of the law. However, there is a chance that unauthorized persons will see the subjects’ PHI. All records will 
be kept in a locked file cabinet or maintained in a locked room at the 
participating sites. Electronic files will be password protected behind an academic institutional  firewall. Only people who are involved in the 
conduct, oversight, monitoring, or auditing of this study will be allowed 
access to the PHI that is collected. Any publications from this study 
will not use information that will identify subjects. Organizations that 
may inspect and/or copy research records maintained at the 
participating sites for quality assurance and data analysis include 
groups  such as the National Cancer Institute (NCI) and Food and 
Drug Administration (FDA).  
3.8.2 Potential benefits  
There is no guarantee of benefit to subjects who enroll in this protocol. 
However, seasonal influenza vaccine is considered beneficial to most subjects, as it generally provides protective immunity against the influenza strains within the vaccine. It is also considered standard of care for patients with hematologic malignancies . Data from this study may yield a better 
understanding of the current body of knowledge describing human infections with influenza viruses. 
4. PATIENT SELECTION  
4.1 Inclusion criteria  
4.1.1 Patient must have a plasma cell dyscrasia that fits in the  IMWG diagnostic 
criteria15. 
4.1.2 Both men and women of all races and ethnic groups are eligible for this 
study.  
4.1.3 Age > 18 years.  Because plasma cell dyscrasias are extraordinarily rare 
in a pediatric population, children are excluded from this study.  
4.1.4 ECOG performance status < 3 (Karnofsky >30%, see Appendix A)  is 
required for eligibility.   
4.1.5 Patient must be eligible to receive standard of care influenza vaccination.  
If the patient has a history of egg allergy  with symptoms more severe than 
urticaria, e.g. angioedema, respiratory distress, lightheadedness, or 
recurrent emesis, they remain eligible to receive influenza vaccination but 
must receive the vaccine in a facility able to recognize and manage 
severe all ergic reactions. Persons who are able to eat lightly cooked egg 
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
12 
 (e.g., scrambled egg) without reaction are unlikely to be allergic, although 
egg-allergic persons might tolerate egg in baked products  
4.1.6 Ability to understand and the willingness to sign a written informed consent document.  
4.2 Exclusion Criteria  
4.2.1 Patients who have already received the seasonal influenza vaccine in the current season.  
4.2.2 History of Guillain -Barré Syndrome  
4.2.3 Patients with a previous severe allergic reaction to influenza vaccination 
or PCV13 . 
4.2.4 Expected survival < 9 months  
4.2.5 Prisoners  
5. REGISTRATION, ACCRUAL , AND EARLY TERMINATION  
5.1 Accrual   
5.1.1 Enrollment  overall  
The research team member obtaining informed consent will tell the patient 
that (1) participation is voluntary, (2) participation or non- participation 
will not affect their usual care and management, and (3) patient confidentiality will be maintained if  the results of the study are published. 
The potential toxicities of protocol therapy and the study calendar will be 
explained to the potential participant. Patients will be provided with a consent form to review, and an opportunity to discuss the study and ha ve 
all questions answered.   
5.1.2 Registration Process  
Patients will be registered after meeting all entry requirements and signing of the informed consent document.  To register a patient, the following should be completed   
• Signed patient consent form  
• HIPAA authorization form (if separate from consent from)  
 At Winship Cancer Institute [Emory], t he research coordinator will verify 
eligibility  per standard Clinical Trials Office procedures .  To complete the 
registration process, the research coordinator will  
 
• register the patient on the study 
• assign the patient a study sequence ID  
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
13 
 5.1.3 Strategies for recruitment and retention  
This protocol follows NIH policy on inclusion of women and minorities as 
participants in research involving human subjects.    No incentives are provided to patients for trial participation.   
5.1.4 Initial treatment arms  
The total sample size of 148 patients will be split equally between the 
single versus 3- shot arms . 
5.1.5 Method of treatment allocation 
A patient number will be assigned upon registration. 
5.1.6 Estimated accrual  based on race, ethnicity and gender  
Ethnic Category  Sex/Gender  
Females   Males   Total  
Hispanic or Latino  3 + 4 = 15 
Not Hispanic or Latino  61 + 80 = 165 
Ethnic Category: 
Total of all subjects  64 + 84 = 148 
Racial Category   
American Indian or 
Alaskan Native  1 + 0 = 1 
Asian  1 + 2 = 3 
Black or African 
American  10 + 18 = 28 
Native Hawaiian or 
other Pacific Islander  1 + 0 = 1 
White  51 + 64 = 115 
Racial Category: 
Total of all subjects  64 + 84 = 148 
 
5.2 Duration of therapy  
Patient may remain on study until one of the following criteria applies:  
 
• Intercurrent illness that prevents administration of vaccine  or follow- up, 
• Per physician discretion in the setting of unacceptable adverse event(s), or 
other medical condition or situation occurs such that continued participation in 
the study would not be in the best interest of the participant .  In patients who 
are randomized to the experimental arm only, s pecific adverse events include 
grade 3 adverse event that occurs without alternative etiology in the 7 days following the first study vaccination  
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
14 
 • Patient decides to withdraw from the study, or  
• General or specific changes in the patient's condition render the patient 
unacceptable for further treatment in the judgment of the PI . 
• Termination or suspension of the study for safety reasons  
5.3 Duration of follow -up 
Patients will be followed for 4 weeks after removal from study and patient records 
will be reviewed until death or 2 years from enrollment (whichever comes first) to assess progression and survival.  Patients removed from study for unacceptable adverse event(s) will be followed until resolution or stabilization of the adverse event.  
5.4 Criteria for removal from study  
Patients will be removed from study when any of the criteria listed in Duration of 
therapy  applies.  The reason for study removal and the date the patient was 
removed must be documented in the appropriate case report f orm. 
5.5 Early stopping rules  
If there are any deaths possible, probably, or definitely related to protocol therapy, 
the trial will be suspended and t he DSM C will provide  recommendations for  
proceeding with the  study to the PI .  
5.6 Premature termination or suspension of the study 
This study may be suspended or prematurely terminated if there is sufficient cause.  Written notification, documenting the reason for study suspension or termination, will be provided by the suspending or terminating party to the investigator, funding agency (as applicable)  and regulatory authorities. If the study 
is prematurely terminated or suspended, the PI will promptly inform the IRB and will provide the reason(s) for the termination or suspension.  Circumstances that may warrant termination or suspension include, but are not limited to:  
 
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stopping Insufficient compliance 
to protocol requirements  
• Data that are not sufficientl y complete and/or evaluable 
• Determination of futility  
6. STUDY PROCEDURES & SCHEDULE  
6.1 Agent administration  
Treatment will be administered on an outpatient basis.  Reported adverse events and potential risks of protocol therapy are described in  the pharmaceutical section.    
 
WINSHIP 4709- 19 SANOFI ISS FIM00017  
 
15 
 No investigational or commercial agents or therapies other than those described in 
this protocol  may be administered with the intent to vaccinate the patient for 
influenza or S. pneumoniae . 
6.1.1 Experimental  arm – Intense Fluzone HD 
Fluzone HD vaccine  for a total of 3 doses beginning at the time of 
enrollment  
6.1.2 Control  arm – Single Fluzone HD 
Fluzone HD vaccine  once at the time of enrollment for a total of 1 dose.  
6.2 Definition of dose- limiting toxicity  
N/A 
6.3 Standard of care study procedures  
See Standard of care and research interventions  
6.4 Research specific procedures 
See Standard of care and research interventions  
   
   
 
16 
 6.5 Schedule of events  
Experimental arm  
Assessment  Screening +  
First visit  Week 
5a Week 
9a Week 
17a Week  
21a 
Signed informed consent  X     
Vital signs  X     
CBC /d/pd X     
CRP, Serum IG’s, LDH  X     
Myeloma proteinse X    X 
Blood for researchf 40 mL  40 mL    40 mL  
Fluzone HD  X  X X  
Prevnar (PCV13)   X    
Record grade ≥ 2 adverse eventsg X  X X  
Influenza -like illness updateb  X X X X 
PFS and OSh     X 
 
Control arm 
Assessment  Screening + First Visit  Week 5a Week 9a Week 17a Week 21a 
Signed informed consent  X     
Vital signs  X     
CBC /d/pd X     
CRP, Serum IG’s, LDH  X     
Myeloma proteinse X    X 
Blood for researchf 40 mL  40 mL    40 mL  
Fluzone HD  X     
Prevnar (PCV13)   X    
Record grade ≥ 2 adverse eventsg X     
Influenza -like illness updateb  X X X X 
PFS and OSh     X 
   
 
17 
 a. Assessments on these days can be performed within a ± 5 day window.   Subsequent visits (weeks 5, 9, 17 , 21) are based on the 
actual time of Fluzone HD vaccination, not the pneumonia vaccination.   
b. Involves contact between study personnel and the patient regarding influenza- like illness  and SAEs.  An in- person visit is not 
required.  
c. All patients (N= 148) will have research blood drawn for correlative science. In both arms, blood will be obtained at baseline, week 
5, and week 21.  The first 20  patients in each group (n= 40 total), split evenly between intervention arm ( 20 experimental, 20 
control), had additional blood drawn 1 week after each Fluzone HD dose  (week 2 for control arm and week s 2, 10, and 18  in the 
experimental arm ) – this was completed 17 -Nov-2019.   
d. CBC, differential, and platelets w ill be performed pre -vaccination.  
e. If not done with results available within 30 days of initial vaccination, a modified myeloma disease assessment  requested but not 
required to include SPEP and free light chains if either were measurable per IMWG criteria in the past.  Serum  IgD or IgE are 
requested  if a monoclonal IgD or IgE were present in the past.  For patients with an IgA monoclonal protei n, Hevylite IgA can be 
used to replace serum immunoglobulins and SPEP . 
f. Peripheral blood samples will be obtained and analyzed as described in correlative science section.   
g. Adverse events related to vaccination will be assess ed on day of vaccination, and 7 days after each Fluzone HD vaccination (in-
person visit for significant adverse events ).  If patient is unable to be seen in- person, every effort will be made to obtain 
documentation of patient evaluation, treatment, and resolution of vaccine- related toxicities.  
h. Survival information will be collected through chart review only .  An in -person clinic visit is not required.  
   
 
18 
 6.6 Dose levels for protocol -specific drugs   
N/A 
6.7 Dose interruptions  
N/A 
6.8 Dose reduction for overlapping  toxicities  
N/A 
 
7. PHARMACEUTICAL INFORMATION  
Complete production and toxicity information for commercial agents can be found in the 
appropriate FDA approved package insert .  Investigator brochure for study agent describes 
preclinical results and clinical experience to date.  
 The investigator shall take responsibility for and shall take all steps to maintain appropriate records and ensure appropriate supply, storage, handling, distribution and usage of investigational product s in accordance with the protocol and any applicable laws and 
regulations. 
7.1 Fluzone HD 
Fluzone HD refers to QIV formulation for 2020- 2021 season.  
 
   
 
19 
  
 
Fluzone  HD refers to TIV formulation for 2019- 2020 influenza season  

   
 
20 
  
7.1.1 Formulation, appearance, packaging, and labeling 
Fluzone HD (TIV) [2019 -2020] is supplied as a single -dose, prefilled syringe, 
without needle, 0.5 mL, in a package of 10.  
 
Fluzone HD Quadrivalent (QIV) [2020 -2021] is supplied as a single -dose, 
prefilled syringe, without needle, 0.7 mL, in a package of 10.  
 Clinical supplies will be affixed with a clinical label in accordance with regulatory requirements.  
7.1.2 Product storage and stability  
Fluzone HD will be stored at 2- 8ºC 
 The temperature of the storage unit must be recorded daily (excluding non-business days and holidays as applicable), monitored during the duration of the trial per the sites’ standard operating procedures, and documentation will be maintained. If the temperature fluctuates outside of the required range, the affected study product(s) must be quarantined at  the correct storage 
temperature and labeled as ‘Do Not Use’ (until further notice). The  
pharmacist must alert the site principal investigator and study coordinator, if the temperature fluctuates outside of the required range. In the event the temperature fluctuates outside of the  required range, including accidental 
deep -freezing or disruption of the cold chain, the affected study product(s) 
must not be administered. Based on the information collected, the  
manufacturer will determine whether the affected study product(s) can be used. If it cannot be  used, the site will receive specific instructions on how to 
return the affected study product(s) to the manufacturer or destroy it on site.  

   
 
21 
 7.1.3 Route of administration 
Each dose of study vaccine will be administered via a single IM injection 
given in the deltoid muscle of the subjects’ preferred arm. Aseptic technique 
will be  used for the withdrawal and administration of each dose of study 
vaccine using a disposable sterile needle appropriate in length for each 
subject and a disposable sterile syringe.  
7.1.4 Returns, reconciliation, and destruction  
The investigator is responsible for keeping accurate records of the clinical 
supplies received from pharmaceutical supply  or designee, the amount 
dispensed to and returned by the subjects and the amount remaining at the conclusion of the trial.  
 Sponsor/Investigator drug destruction is allowed provided the following minimal standards are met:  
• On-site disposal practices must not expose humans to risks from the 
drug.  
• On-site disposal practices and procedures are in agreement with 
applicable laws and regulations, including any special requirements for 
controlled or hazardous substances.  
• Written procedures for on- site disposal are available and followed. The 
procedures must be filed with the Sponsor SOPs and a copy provided to 
pharmaceutical supporter  upon request.  
• Records are maintained that allow for traceability of each container, 
including the date disposed of, quantity disposed, and identification of the 
person disposing the containers. The method of disposal, ie, incinerator, 
licensed sanitary landfill, or licensed waste disposal vendor must be 
documented.  
• Accountability and disposal records are complete, up -to-date, and 
available for pharmaceutical supporter  to review throughout the clinical 
trial period as per the study agreement.  
 
It is the Investigator’s responsibility to arrange for disposal of all empty 
containers, provided that procedures for proper disposal have been established according to applicable federal, state, local, and institutional guidelines and procedures, and provided that appropriate records of disposal are kept.  
 Upon completion or termination of the study, all unused and/or partially used investigational product will be destroyed at the site per institutional policy. It is the Investigator’s responsibility to arrange for disposal of all empty containers, provided that  procedures for proper disposal have been established 
according to applicable federal, state, local and institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
   
 
22 
 7.1.5 Expected adverse events / toxicities   
Adult recipients of inactivated influenza virus  vaccines may develop 
influenza -like reactions such as fever, feverishness (chills/shivering/  
sweating), gastrointestinal side effects (emesis and diarrhea), fatigue 
(tiredness), malaise (general unwell feeling), myalgia (body aches/muscular  
pain), arthralgia (joint pain), headache, and/or nausea. Some subjects may develop reactions  at the injection site, including pruritus (itching), ecchymosis 
(bruising), erythema (redness), induration (hardness)/swelling, pain, and/or tenderness. With unadjuvanted licensed,  
inactivated influenza virus vaccines most of these reactions peak in intensity in the first 24 hours  after vaccination and usually disappear without treatment 
within 1 or 2 days. Analgesics (e.g., acetaminophen, or ibuprofen or similar non-steroidal anti- inflammatory drugs (NSAIDs)) and rest may generally 
relieve or lessen these reactions. Bruising can sometimes occur due to the  
vaccination procedure.  
 In addition, post -marketing surveillance indicates the following adverse 
events of special interest  (AESI) as potential risks for pandemic vaccines 
based on those identified for the seasonal  influenza vaccines: neuritis, 
convulsions, severe allergic reactions, encephalitis, thrombocytopenia, vasculitis, and Guillain -Barré (GBS) syndrome. Reports of these reactions 
were rare; however, exact incidence rates cannot be precisely calculated.   
 Acute and potentially life -threatening allergic reactions are also possible. Very 
rarely, occurring  in about 1 in 4 million people given a vaccination, there can 
be a serious allergic reaction to a vaccine. These reactions can manifest as 
skin rash (hives), swelling around the mouth, throat  or eyes, difficulty 
breathing, a fast pulse, or loss of blood pressure. If these reactions occur,  
they can usually be stopped by the administration of emergency medications by the study personnel. As with any vaccine or medication, there is a very small chance of a fatal reaction  (death), although researchers do not expect 
this to occur.  GBS : During the swine influenza (H1N1) vaccine campaign of 1976, some 
recipients developed a paralytic illness called Guillain -Barr. syndrome (GBS). 
GBS is an acute inflammatory  neuropathy characterized by weakness, 
hyporeflexia or areflexia, and elevated protein  concentrations in cerebrospinal 
fluid. The rate of GBS was significantly increased in individuals  receiving the 
1976 swine influenza (H1N1) vaccine at about 1 per 100,000 vaccine recipients.  This syndrome has not been seen consistently with other influenza 
vaccines. Most persons  who develop GBS recover completely, although the 
recovery period may be as little as a few  weeks or as long as a few years. 
About 30% of those with GBS still have residual weakness  after 3 years and 
about 3% may suffer a relapse of muscle weakness and tingling sensations  
many years after the initial attack. Intensive surveillance of GBS after administration of  inactivated influenza vaccines since 1976 has shown a slight 
   
 
23 
 increase in risk over background cases (more than one additional case of GBS 
per million persons) following vaccination, typically with onset within 6 weeks after vaccination
36. Interestingly, although vaccination rates have 
increased in the last 10 years the numbers of reported cases of vaccine -
associated  GBS have declined37. A recent study in Canada showed that the 
2009 H1N1 vaccine was  associated with a small but significant risk of GBS in 
persons 50 years and older38. An active, population- based surveillance study 
conducted during the 2009- 2010 influenza season found less than 1 excess 
GBS case per million doses of 2009 H1N1 vaccine administered – a  rate 
similar to that associated with some previously administered annual influenza vaccines
39,40. Another study using the Medicare system showed an elevated 
risk of GBS with 2009 monovalent H1N1 vaccination (incidence rate ratio = 2.41, 95% confidence interval: 1.14, 5.11;  attributable risk = 2.84 per million 
doses administered, 95% confidence interval: 0.21, 5.48)
41. An international 
collaboration study also supported a conclusion of an association between 2009 H1N1 vaccination and GBS
42. 
   
   
 
24 
 8. CORRELATIVE/SPECIAL STUDIES  
Assessment of biomarkers and changes relevant to influenza vaccination  are paramount in this 
protocol.   
 
 
8.1 Objective for lab 1  - Sanofi  
8.1.1 Collection of specimens  
Peripheral blood will be drawn at baseline, week 5, and week 21.  
8.1.2 Specimen handling 
Blood will be cryopreserved by the Dhodapkar laboratory and batch shipped 
to a central laboratory at Sanofi for processing. 
8.1.3 Specimen analysis  
HAI titer will be assessed.  
8.1.4 Site performing study  
Sanofi  
8.2 Objective for lab 2  – Dhodapkar  laboratory  
8.2.1 Collection of specimens  
30-40 mL  of peripheral blood will be drawn, labeled and logged under the 
supervision of the principal investigator and in accordance with site specific SOPs.  
 Correlative Objective  IHC/Assay/Test  Tissue/Body Fluid Tested  
and Timing of Collection  
Determine seroconversion 
and seroprotection  HAI titer  Peripheral blood at baseline, week 5 , 
and week 21 
B-cell and CD4 T -cell 
responses  Mass cytometry  & other 
immunologic assays  Peripheral blood at baseline, week 5, 
and week 21 .   
   
 
25 
 8.2.2 Specimen handling 
Specimens will be shipped to the Dhodapkar  laboratory for processing – see 
protocol specific tissue collection worksheet.  
8.2.3 Specimen analysis  
• Mass cytometry: Phenotypic analysis of T and B cells, including 
plasmablasts and TFH cells will be performed by mass cytometry utilized 
a panel as described.43  
• Pneumococcal antibody responses by Elisa  
• Antigen- specific T cells (CRM -197 and HA -specific T cells; T cells specific 
to control viral antigens (CMV, EBV).  
• B cell receptor sequencing (selected cases)  
• Single cell transcriptome analysis (selected cases).  
8.2.4 Site performing study  
Dhodapkar  laboratory  
 
  
   
 
26 
 9. RESPONSE  
 
Time to progression  (TTP) : Time to progression is defined as the time from  last treatment  until 
progression. Patients who have died without evidence of progression are censored in the TTP 
analysis at the time of death and patients who are alive without progression are censored at the last disease assessment.   
 Progression -Free Survival (PFS) : Defined as the time from last treatment to the disease 
progression or death from any cause. Patients who have not progressed or died are censored at the date last known progression- free. Patients with no on- study assessment will be censored at 
the time of registration.  
 Overall survival (OS) : OS is defined as the time from randomization to death. Alive patients are 
censored at the date last known alive.   
 
10. STATISTICAL CONSIDERATIONS  
10.1 Statistical hypotheses  
This is a randomized study to determine whether three doses of Fluzone  HD, aka 
continuous dosing throughout the influenza  season will maintain seroprotection 
throughout the entire study.  Specifically we hypothesize that 58% of patients in the experimental arm will achieve seroprotection  at week 21 , e.g. HAI>40;  the null 
hypothesis is that only 33% will demonstrate seroprotection at the end of the study.   
10.2 Analysis datasets  
Safety Population : The safety analysis dataset will include all  eligible patients who 
begin treatment and receive at least one dose of protocol therapy. Patients will be 
analyzed in the cohort to which they were enrolled.  Efficacy Evaluable Population : All evaluable patients will be included in the 
analysis of efficacy  endpoint. T he term evaluable is defined as any eligible patient 
who receives at least one dose of protocol therapy and does not withdraw consent  
until the patient’s first response assessment.  P atients who fail to have a response 
assessment due to early progression or death will be categorized as non -responders.  
10.3 Sample size determination  
In the initial design, the sample sizes of 81 in each group achieved 90% power to detect a difference between the group proportions of 0.2520. T he proportion in group 
one (the intense Fluzone HD arm) is assumed to be 0.3330 under the null hypothesis 
and 0.5850 under the alternative  hypothesis. The proportion in group two (the control 
group) is 0.3330. The test statistic used is the two -sided Z test with pooled variance.  
The significance level of the test (the alpha) was targeted  at 0.0500, i.e. the 
probabi lity of rejecting a true null hypothesis that was desired. The significance level 
   
 
27 
 actually achieved by this design is 0.0513.  The planned power was 0.9, i.e. the 
probability of rejecting a false null hypothesis. We assume 10% drop off rate in the study so that we planned to enroll 90 patients in each group.  
 During the first influenza season (2019- 2020), we enrolled 50 patients  of which only 
23 were evaluable as 27 patients missed the week 21 study assessment due to 
COVID19 .   
 
We aim to complete the trial during the influenza season 2020- 2021, and hence will 
need to control season as a confounder through a logistic regression model. A logistic regression of a binary response variable (e.g. HAI>40) on a binary independent variable (e.g. the treatment arms) with a sample size of 134 observations (of which the two treatment arms are evenly distributed ) achieves 80% power at a 0.05 
significance level to detect a change in the rate of HAI>40 from the baseline value of 0.333 to 0.585. This change corresponds to an odds ratio of 2.82. An adjustment was made since a multiple regression of the independent variable of interest on the other independent variables (e.g. the seasons) in the logistic regression obtained an R -
Squared of 0.1. Henc e we will need 67 patients in each randomized arm. After taking 
into account the expected 10% dropout rate, we plan to enroll 74 patients in each arm , 
producing a total sample size of 148 patients .  Given we already accrued  11 evaluable  
patients  per arm during the first season, we will plan to enroll an additional 125 
patients  in the second season. 
10.4 Statistical methods   
10.4.1  Design operating characteristics  
N/A 
10.4.2  Safety analyses  
Adverse event data will be described  and graded per the NCI CTCAE  
guidelines. For each adverse event, information to  be collected includes  event  
description, time of onset, clinician  assessment  of severity, relationship to 
study product  (assessed only by those  with the training and authority to make 
a diagnosis), and time of resolution/stabilization of  the event.  All vaccine-
related AE s will be recorded with start dates  occurring any time after patient 
receives any study drug until 7 (for non- serious AEs) or 100 days (for SAEs) 
after the last day of study  participation. At each study visit, the investigator 
will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization.  Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, 
if the study participant’s  condition deteriorates at  any time during the study, it  
will be recorded as  an AE.  Changes in the severity of an AE will be  
documented to allow an assessment of the duration of the event at each level 
   
 
28 
 of severity to be performed. AEs characterized as intermittent require 
documentation of onset and duration of each episode.  The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. 
Adverse events will be summarized and described within each cohort. They 
will initially be reviewed regardless of attribution, but also whether they are 
possibly, probably, or definitely related to treatment. In addition, we will review all adverse event data that are graded as 3, 4, or 5 and classified as either “unrelated” o r “unlikely to be related” to study treatment in the event of 
an actual relationship developing. The incidence of severe adverse events or toxicities will be described. We will assess the proportion of patients who experience grade 3 or higher non- hematologic toxicity. To assess tolerability, 
we will also capture the proportion of patients who go off treatment due to adverse events.   Temporary suspension of enrollment 
due to toxicity (a ka stopping rules) are 
described elsewhere.   
10.4.3  Baseline descriptive statistics  
Baseline characteristics will be summarized within each cohort  using 
descriptive statistics. For categorical variables, frequencies and percentages will be presented. For continuous variables, the median and range will be presented.  Inferential tests will not be performed.  
10.4.4  Planned interim analyses (if applicable)  
N/A 
10.4.5  Analysis of influenza response and disease status endpoints  
HAI will first be measured and summarized with mean and standard deviation at different time -points, respectively. Paired t -test will be further used to test 
whether there is significant change in HAI at different time point s from 
baseline, respectively. Two sample t -test will be used to compare the change 
in HAI from baseline between two groups, at different time -point, 
respectively. Chi -Square test will be used to compare the Seroconversion and 
Seroprotection between two groups, respectively. Logistic regression model will be used to compare adjusted difference in Seroconversion and Seroprotection between two groups after adjusting for other factors, respectively.  
 Spearman/Pearson correlation coefficient will be used to measure the relationship between correlation between HAI, predefined risk of influenza -
like illness (low, moderate, high), respectively. Finally Mixed model will be employed to test their correlations over the whole period with and without 
   
 
29 
 adjusting for other factors, respectively. Kaplan Meir method, Log- rank test, 
and Cox model will be used to test the relationship between peak HAI and 
PFS.  
   
10.4.6  Analysis of secondary endpoints   
Time to event outcomes including TTP, PFS and OS  will be assessed with  
patients censored at time of last follow -up. TTP, PFS and OS  rates of two 
patient groups will be  estimated with the Kaplan -Meier method and compared 
between different groups using the log- rank test, respectively. The TTP, PFS 
and OS  of each patient group at specific time points, such as 1 year, 3 years, 
and 5 years, etc. will be estimated alone with 95% CI. Cox proportional hazards 
models will be used in the multivariable analyses to assess adjusted effects of 
biomarkers on the patients’ TTP, PFS and OS  after adjusting for other factors. 
The proportional hazards assumption will be  evaluated graphicall y and 
analytically with regression diagnostics.  
 
Protocol therapy related toxicities rate will be summarized using descriptive statistics such as frequencies and proportions. Differences in the proportion of patients who experience protocol -related toxicities will not be compared 
between cohorts.  
 
10.5 Measure to minimize bias 
10.5.1  Randomization 
The total sample size of 148 patients will be split equally between the arms.  
10.5.2  Evaluation of success of blinding (N/A)  
10.5.3  Breaking the study blind / participant code (N/A)  
 
11. ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS  
11.1 Identification of AEs and follow -up 
The occurrence of an AE or SAE may come to the attention of study personnel during 
study visits and interviews of a study participant presenting for medical care, or upon review by a study monitor.   The only adverse events to be captured in this protocol must relate to vaccination or influenza -like illness , and these will be captured  on the appropriate 
CRF. Changes in the severity of these AE ’s only will be  documented to allow an 
assessment of the duration of the event at each level of severity to be performed. These AEs will be followed to adequate resolution. 
   
 
30 
  
Information to  be collected includes  event  description, time of onset, clinician  
assessment  of severity, relationship to study product  (assessed only by those  with the 
training and authority to make a diagnosis), and  time of resolution/stabilization of  the 
event.   
 
Any medical condition that is present at the time that the participant is screened will 
be considered as baseline and not reported as an AE. Unanticipated problems will be  
recorded in  the data collection system throughout  the study. 
 
The site PI  will record all reportable events with start dates  occurring any time after 
patient receives the any study drug until 7 (for non- serious AEs) or 14 days (for 
SAEs) after the last day of study participation. At each study visit, the investigator 
will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization. 
11.2 Expectedness 
Expected adverse reactions are AEs that are common and known to occur for the study agent being studied and should be collected in a standard, systematic format using a grading scale based on functional assessment or  magnitude of reaction. 
Describe the method of determining the expectedness of an AE. Expectedness refers to the awareness of AEs previously observed, not based on what might be anticipated from the properties of the study agent.  An AE or suspected adverse reaction is considered "unexpected" if it is not  listed in 
the current Investigator’s Brochure (IB) , consent, or is not listed at the specificity or 
severity that has been observed. "Unexpected," as used in this definition, also refers to AEs that are mentioned in the IB as occurring with a class  of drugs  or as 
anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the drug under  investigation. 
 The PI , working together with treating physician, will be  responsible for determining 
whether an AE is expected or unexpected. An AE will be considered unexpected if 
the nature,  severity, or frequency of the event is not consistent with the  risk 
information previously described in the IB for the study agent. 
11.3 Adverse event characteristics  
CTCAE term (AE description) and grade:  The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) will be utilized for AE reporting.  A copy of the CTCAE version can be downloaded from the Cancer Therapy Evaluation Program ( CTEP ) web site 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
.   
 For all collected AEs, the clinician who examines and evaluates the participant will determine the AE’s causality based on temporal relationship and his/her clinical 
   
 
31 
 judgment.  The degree of certainty about causality will be graded using the categories 
below:  
 
• Definitely  Related – There is clear  evidence to suggest  a causal relationship, 
and other possible contributing factors  can be ruled out.  The clinical  event, 
including an abnormal laboratory  test result,  occurs in a plausible time 
relationship to drug administration and cannot be explained by concurrent  
disease or other drugs or  chemicals. The response to withdrawal  of the drug 
should be clinically plausible. The event  must  be pharmacologically  or 
phenomenologically  definitive,  with use of a satisfactory  re-challenge procedure if 
necessary.  
• Probably Related –  There is evidence  to suggest a causal relationship, and the 
influence of other  factors  is unlikely. The  clinical event, including an abnormal 
laboratory  test result, occurs  within  a reasonable time after  administration  of the 
drug, is  unlikely to  be attributed to concurrent disease or other  drugs or  
chemicals, and follows  a clinically reasonable response on withdrawal.  Re-
challenge information is not required to fulfill this definition.  
• Possibly Related – There is some evidence  to suggest  a causal  relationship 
(e.g., the event  occurred  within  a reasonable time after  administration of  the trial 
medication).  However, other  factors  may have contributed to the  event (e.g., the 
participant’s clinical  condition, other  concomitant  events). Although an AE may 
rate only as “possibly related”  soon after discovery, it can be flagged as  requiring 
more information and later  be upgraded to “probably  related” or  “definitely 
related,” as  appropriate.  
• Unlikely to be related – A clinical event, including an abnormal laboratory test 
result, whose  temporal relationship to drug administration  makes a  causal  
relationship improbable (e.g., the event  did not occur within  a reasonable time 
after administration of the trial medication) and in which  other drugs  or chemicals 
or underlying disease provides  plausible explanations (e.g.,  the participant’s 
clinical condition,  other  concomitant  treatments).  
• Not Related –  The AE is  completely independent  of study drug administration,  
and/or  evidence exists  that the event is definitely related  to another  etiology. 
There must  be an alternative,  definitive  etiology documented by the clinician.  
 The determination of causality will include some of the following characteristics: 
 
Exposure  Is there evidence that the subject was exposed to the product 
such as: reliable history, acceptable compliance assessment (pill count, diary, etc), expected pharmacologic effect, or 
measurement of drug/metabolite in bodily specimen?  
Time course  Did the AE follow in a reasonable temporal sequence from 
administration of the product?  Is the time of onset of the AE 
compatible with a drug -induced effect?  
Likely cause  Is the AE not reasonably explained by another etiology such 
as underlying disease, other drug/vaccine, or other host or 
environmental factors  
Dechallenge  Was the product discontinued or exposure reduced?  If yes, 
did the AE resolve or improve?   
   
 
32 
 Rechallenge  Was the subject re -exposed to the product in this study?  If 
yes, did the AE recur or worsen?  
Consistency with 
trial treatment 
profile  Is the clinical presentation of the AE consistent with previous 
knowledge regarding the product or drug class?  
 
11.4 Definition of serious adverse event (SAE)  
The only adverse events to be captured in this protocol must relate to 
vaccination or influenza -like illness .  Within this definition, a n AE is considered 
"serious " if, in the  view of either the investigator or sponsor, it results in any of the  
following outcomes:   
• Death,  
• Is life-threatening  
• Inpatient hospitalization  (>24hrs) or prolongation of existing  hospitalization,  
• A persistent  or significant incapacity or substantial disruption of the ability to 
conduct normal life functions, or  
• A congenital anomaly/birth defect.  
 Important medical events that may not result in death, be life -threatening, or require 
hospitalization may be  considered serious when, based upon appropriate medical 
judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.   Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home  thought to be related to an influenza -like 
illness  or influenza vaccination. 
 Events not considered to be serious adverse events (SAEs) are hospitalizations for  
 
• Routine treatment or monitoring of the studied indication, not associated with 
any deterioration in condition, or for elective procedures of a condition 
unrelated to the studied condition or its treatment  
• Elective or pre -planned treatment for a pre -existing condition that did not 
worsen 
• Emergency outpatient treatment for an event not fulfilling the serious criteria 
outlined above and not resulting in inpatient admission  
• Respite care  
 
Distinction between seriousness and severity of an AE . Severity is a measure of 
intensity of an event (mild, moderate, severe). However, the event itself may be of relatively minor medical significance; thus, a severe reaction may not necessarily be classified as a serious reaction. This differs from seriousne ss, which is based on 
patient/event outcome or action criteria described above and are usually associated with events that pose a threat to a patient’s life or functioning. A severe adverse event 
   
 
33 
 does not necessarily need to be considered serious. Seriousness (not severity) serves 
as a guide for defining regulatory reporting obligations.   Any vaccine-  or influenza -like illness related -AE considered serious must be 
submitted on an SAE form to the Data and Safety Monitoring Committee ( DSMC )
 if 
one exists for the study.  The DSM C may request to receive real -time notification of 
all SAEs or only SAEs thought to be related to study agent.  
 All SAEs will be followed until satisfactory resolution or until the site investigator deems the event to be chronic or the adherence to be stable. Other supporting documentation of the event may be requested by the study sponsor and should be provided as soon as possible. The study sponsor will be responsible for notifying FDA of any unexpected fatal or life -threatening suspected adverse reaction as soon as 
possible but in no case later than 7 cal endar days after the sponsor's initial receipt of 
the information. 
11.5 Definition of unanticipated problems (UP) and reporting requirements  
The Office for Human Research Protections (OHRP)  considers unanticipated 
problems involving risks to participants or others to include, in general, any incident, experience, or an outcome that meets all  the following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research 
procedures that are described in the protocol -related documents, such as the 
IRB-approved research protocol and informed consent document; and (b) the 
characteristics of the parti cipant population being studied;  
• Related or possibly related to participation in the research (“possibly related” 
means there is a reasonable possibility that the incident, experience, or outcome 
may have been caused by the procedures involved in the research); and  
• Suggests that the research places participants or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously 
known or recognized.  
 
This study will use the OHRP definition of unanticipated problems. Incidents or 
events that meet the OHRP criteria for UPs require t he creation and completion of a  
UP report form. It is the site investigator’s responsibility to report UPs to their IRB and to the DCC/study sponsor. The UP report will include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the 
IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, 
or outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have 
been taken or are proposed in response to the UP.  
 
The PI  will make an assessment of whether the event constitutes an unanticipated 
problem posing risks to subjects or others (UP). This assessment will be provided to 
   
 
34 
 the Emory University IRB.  If the Emory IRB determines an event is a UP it will 
notify the appropriate regulatory agencies and institutional officials. 
11.6 Expedited adverse event reporting  
All serious adverse events that occur after  the date of informed consent signature, 
during treatment, or within 14 days of the last dose of study drug must be reported on a MEDWATCH FDA Form 3500A to the principal investigator . If a patient is 
permanently withdrawn from the study because of a SAE, this information must be included in the initial or follow -up SAE report form. 
 
11.6.1  Reporting to Sanofi  
SAE reports and reports of adverse events of special interest will be submitted to Sanofi Pharmacovigilance within 1 business day.   
11.6.2  Non-serious adverse event reporting 
Non-serious adverse events will be reported on the adverse event case report 
form(s).  
11.6.3  Reporting to the institutional review board (IRB)  
Clinical trials office (CTO) staff will report all serious adverse events directly to the IRB  according to IRB reporting requirements .   
11.6.4  Coordinating center reporting to the food and drug administration (FDA)  
The Principal Investigator  will be responsible for all applicable 
communication with the FDA.  
 Unexpected fatal or life- threatening experiences associated with the use of the 
study treatment will be reported to FDA as soon as possible but no later than 7 calendar days after initial receipt of the information.   
 All other serious unexpected experiences associated with the use of the study treatment will be reported to FDA as soon as possible but in no event later than 15 calendar days after initial receipt of the information. Events will be reported to the FDA by telephone (1 -800-FDA -1088) or by fax (1- 800- FDA -
0178) using MEDWATCH Form FDA 3500A (Mandatory Reporting Form for investigational agents). Forms are available at http://www.fda.gov/medwatch/getforms.htm
.  
 An annual safety report containing all SAEs, expected and unexpected , will be 
sent to applicable regulatory authorities.  
   
 
35 
 11.7 Monitoring of adverse events and period of observation  
The only adverse events to be captured in this protocol must relate to 
vaccination or influenza -like illness .  These adverse events, both serious and non-
serious, and deaths that are encountered from the date of informed consent signature, throughout the study, and within 14 days of the last study drug treatment administration should be followed to their resolution, or until the participating investigator assesses them as stable, or the participating investigator determines the event to be irreversible, or the participant is lost to follow -up.  
 The presence and resolution of AEs and SAEs (with dates) should be documented on the appropriate case report form and recorded in the participant’s medical record to facilitate source data verification.   
 After this period, only SAEs considered reasonably study- related by the investigator 
must be reported to the sponsor (for example, a delayed SAE) without limitation.  
 
Participants should be instructed to report any serious post -study event(s) that might 
reasonably be related to participation in this study.  
11.8 Second and secondary malignancy  
n/a   
 
12. DATA REPORTING / REGULATORY REQUIREMENTS  
12.1 Source documents and access to source data  
Each participating site will maintain appropriate medical and research records for this trial, in  compliance with relevant federal and institutional requirements pertaining to 
ICH E6 for the protection of confidentiality of participants.    If applicable, a s part  of participating in a NIH IC -sponsored or NIH IC - affiliated 
study, each site will permit authorized representatives of the NIH IC and regulatory agencies to examine (and when permitted by applicable law, to copy) clinical records for the purposes of quality assurance reviews, audits, and evaluation of the  study 
safety, progress, and data validity.  
 Source data are all information, original records of clinical findings, observations, or other  activities in a clinical trial necessary for  the reconstruction and evaluation of the 
trial. CRFs can be source documents as well as the medical record.   
12.2 Quality assurance  
QC procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
   
 
36 
  
Following written SOPs, the monitors will verify that the clinical trial is conducted and data are generated, documented (recorded), and reported in compliance with the protocol.  
The investigational site will provide direct access to all trial related sites, source 
data/documents, and reports for monitoring and auditing by the sponsor, and 
inspection by local and regulatory authorities.  
12.3 Data collection and management responsibilities  
Data collection is the responsibility of the clinical trial staff at  the site under the 
supervision of the site  PI. The  investigator is responsible for ensuring the accuracy, 
completeness, legibility, and timeliness of the data reported.  
 All source documents should be completed in a neat, legible manner to ensure  
accurate interpretation of data. Black ink is required to ensure clarity of reproduced copies. When making changes or corrections, cross out the original entry with a single 
line, and initial and date the change.   
 Copies of the electronic  CRF  (eCRF) will be provided for use as source documents 
and maintained for recording data  for each participant  enrolled in the  study. Data 
reported in the  eCRF derived from  source  documents should be  consistent  with the  
source documents  or the discrepancies  should be  explained and captured in a 
progress  note and maintained in the participant  official  electronic study record.  
 At the coordinating center, c linical data (including AEs, concomitant medications, 
and expected adverse reactions data)  and clinical laboratory d ata will be entered into 
OnCore , a data capture system available at each center. The data system includes 
password protection and internal quality checks, such  as automatic range checks, to 
identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents. 
12.4 Study records retention 
Study  documents  should  be retained  for a minimum of  2 years  after the last approval  
of a marketing application in an  ICH  region and  until there are no  pending or 
contemplated  marketing applications  in an  ICH region  or until  at least  2 years have 
elapsed  since the formal  discontinuation  of clinical development of the investigational  
product. These documents  should be  retained  for a longer  period, however, if required 
by local  regulations.  No records  will be  destroyed without  the written  consent  of the 
sponsor, if  applicable. It is the  responsibility  of the sponsor  to inform  the investigator  
when  these documents  no longer  need  to be retained.  
12.5 Winship Data and Safety Monitoring  (DSMC)  
The Data and Safety Monitoring Committee (DSMC) of the Winship Cancer Institute will provide oversight for the conduct of this study.  The DSMC functions 
   
 
37 
 independently within Winship Cancer Institute to conduct internal monitoring 
functions to ensure that research being conducted by Winship Cancer Institute Investigators produces high- quality scientific data in a manner consistent with good 
clinical practic e (GCP) and appropriate regulations that govern clinical research.    
Depending on the risk level of the protocol, the DSMC review may occur every 6 
months or annually.  For studies deemed High Risk, initial study monitoring will 
occur within 6 months from  the date of the first subject accrued, with 2 of the first 5 
subjects being reviewed.  For studies deemed Moderate Risk, initial study monitoring 
will occur within 1 year from the date of the first subject accrued, with 2 of the first 5 subjects being reviewed.  Subsequent monitoring will occur in routine intervals per the Winship Data and Safety Monitoring Plan (DSMP)
.  
 The DSMC will review pertinent aspects of the study to assess subject safety, compliance with the protocol, data collection, and risk- benefit ratio. Specifically, the 
Winship Cancer Institute Internal Monitors assigned to the DSMC may verify informed conse nt, eligibility, data entry, accuracy and availability of source 
documents, AEs/SAEs, and essential regulatory documents.  Following the monitoring review, monitors will provide a preliminary report of monitoring findings to the PI and other pertinent indi viduals involved in the conduct of the study.  The PI 
is required to address and respond to all the deficiencies noted in the preliminary report.  Prior to the completion of the final summary report, monitors will discuss the preliminary report responses w ith the PI and other team members (when appropriate).  
A final monitoring summary report will then be prepared by the monitor.  Final DSMC review will include the final monitoring summary report with corresponding PI response, submitted CAPA (when applicable), PI Summary statement, and available aggregate toxicity and safety data.   
 The DSMC will render a recommendation and rating based on the overall trial conduct.  The PI is responsible for ensuring that instances of egregious data insufficiencies are reported to the IRB.  Continuing Review submissions will include the DSMC recommendation letter.   Should any revisions be made to the protocol -
specific monitoring plan after initial DSMC approval, the PI will be responsible for notifying the DSMC of such changes.  The Committee reserves the right to conduct additional audits if necessary.  
12.6 Protocol deviations  
A protocol deviation in this protocol relates only to the administration of vaccine – specifically incorrect dose, incorrect timing, incorrect administration procedure (including injection) .  Within this definition, a deviation is any noncompliance with 
the clinical trial protocol, GCP, or MOP requirements. The noncompliance may be  
either on the part of the participant, the investigator, or the study site staff. Because of  
deviations, corrective actions are to be developed by the site and implemented 
prompt ly. 
 These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
   
 
38 
 • 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
 
It is the responsibility of the site to use continuous vigilance to identify and report deviations within 60 working days of identification of the protocol deviation, or within 180 working days of the scheduled protocol -required activity. All deviations 
must be addressed in stud y source documents. Protocol deviations must be  sent to the 
local IRB per their guidelines. The site PI/study staff is responsible for knowing and 
adhering to their IRB requirements.  
12.7 Publication and data sharing policy  
This study will comply  with the  NIH Public  Access  Policy, which  ensures  that the 
public has access to  the published results  of NIH funded research. It requires 
scientists  to submit  final peer -reviewed journal  manuscripts  that arise from  NIH 
funds to the  digital archive  PubMed Central upon acceptance for  publication. 
 The International Committee  of Medical Journal  Editors (ICMJE)  member journals 
have  adopted a clinical trials registration  policy as  a condition for publication. The 
ICMJE defines a  clinical trial as  any research  project that  prospectively assigns 
human subjects  to intervention  or concurrent comparison or control  groups to study 
the cause -and-effect relationship between a medical intervention and a health  
outcome. Medical  interventions include drugs, surgical procedures, devices, 
behavioral  treatments,  process -of-care changes, and the like. Health  outcomes 
include any  biomedical  or health -related  measures  obtained in patients  or 
participants,  including pharmacokinetic  measures and adverse events.  The ICMJE  
policy, and the Section 801 of the Food and  Drug Administration Amendments  Act of 
2007, requires that  all clinical  trials be registered in  a public  trials registry such  as 
ClinicalTrials.gov , which is sponsored by the National  Library  of Medicine.   
12.8 Audit and inspection  
In accordance with GCP, the investigators agree to comply with the requirements of the sponsor and the Regulatory Authorities about  an audit or inspection of the trial.  
 The audit may be performed at any of the stages of the study, from development of the protocol to publication of the results.  
 Regulatory authorities or the sponsor may request access to all source documents, data capture records, and other study documentation for on- site audit or inspection. 
Direct access to these documents must be granted by the investigator, who must provide support always for these activities.   
 
   
 
39 
 13. ETHICS AND PROTECTION OF HUMAN SUBJECTS  
13.1 Ethical standard  
The investigator will ensure that this study is conducted in full conformity with 
Regulations for the  Protection of Human Subjects of Research codified in 45 CFR  
Part 46, 21 CFR Part 50, 21 CFR Part 56, as well as the federal regulations pertaining to ICH E6.  
13.2 Institutional review board 
The protocol, informed consent  form , recruitment materials, and all participant 
materials will be  submitted to the IRB for review and approval. Approval of both the 
protocol and the consent form  must be obtained before any participant is enrolled. 
Any amendment to the protocol will require review and approval by the  IRB before 
the changes are implemented to the study. All changes to the consent form  will be 
IRB approved; a determination will be made regarding whether previously consented participants need to be re -consented.  
13.3 Informed consent  
Consent forms describing in  detail the study agent, study procedures, and risks are 
given to the  participant and written documentation of informed consent  is required 
prior to starting intervention/administering study product.   Informed consent is  a process  that is initiated prior to the individual consent  to 
participate  in the  study and continues  throughout the  individual ’s participation. 
Extensive  discussion of risks and possible benefits  of participation will be provided 
to the  participants and  their families. Consent  forms  will be IRB approved and the 
participant  will be asked  to read and  review  the document. The  investigator  will 
explain  the research study to  the participant  and answer any questions  that may arise.  
All participants  will receive  a verbal  explanation in terms suited to  their 
comprehension of the  purposes, procedures, and potential risks  of the  study and of  
their rights  as research participants.  Participants  will have the  opportunity to 
carefully review  the written  consent form  and ask questions prior  to signing. 
The participants should have the opportunity to discuss  the study with their surrogates 
or think about it prior to agreeing to participate. The participant will sign the informed consent document prior to any procedures being done  specifically for the  study. The 
participants may withdraw consent at any time throughout the course of the trial. A copy of the informed consent document will be given to the participants for their records. The rights and welfare of the participants will be protected by emphasizin g to 
them that the quality of their medical care will not be adversely affected if they decline to participate in this study.  
13.4 Participant and data confidentiality  
Participant  confidentiality  is strictly held in  trust by  the participating investigators, 
their staff, and  the sponsor(s) and their agents. This confidentiality is  extended to 
   
 
40 
 cover  testing of  biological  samples and  genetic tests in addition to the clinical 
information relating to participants.  Therefore,  the study protocol, documentation, 
data, and  all other  information generated will be  held in strict confidence. No 
information  concerning the  study or the  data will be  released to  any unauthorized 
third party without  prior written approval  of the sponsor. 
 
The study monitor, other authorized representatives  of the  sponsor, representatives  of 
the IRB  or pharmaceutical company supplying study product  may inspect  all 
documents and  records  required  to be  maintained by the  investigator, including but 
not limited to,  medical records (office,  clinic,  or hospital)  and pharmacy  records for  
the participants in  this study. The  clinical study site will permit access  to such 
records.  
 
The study participant’s  contact information  will be  securely stored at  each clinical  site 
for internal use  during the study. At  the end of the  study, all records  will continue to  
be kept in a secure location for  as long a period as dictated by local IRB  and 
Institutional regulations. 
 Study participant research data, which is  for purposes  of statistical analysis  and 
scientific reporting,  will be transmitted to  and stored . This  will not include the  
participant’s  contact  or identifying information. Rather, individual participants  and 
their research data will be identified by  a unique study identification number. The  
study data entry  and study management  systems used by clinical sites  and research 
staff will be  secured and password protected. At  the end of the  study, all study 
databases  will be de -identified and  archived . 
13.5 Research use of stored samples, specimens, or data  
13.5.1  Current use  
Samples and data collected under this protocol may be used to study multiple myeloma. Access to stored samples will be limited to IRB -approved 
investigators. Samples  and data will be stored using codes assigned by the 
investigators or their designees. Data will be kept in password- protected 
computers. Only  investigators will have access to the samples and data.  
 All stored samples will be maintained in the laboratory to which it was sent 
initially for analysis. Study participants who request destruction of samples 
will be notified of compliance with such request and all supporting details will be maintained for tr acking.  
13.5.2  Future use  
N/A 
  
   
 
41 
 REFERENCES  
 1. Chemaly RF, Vigil KJ, Saad M, et al: A multicenter study of pandemic influenza A 
(H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer 
118:4627- 33, 2012  
 2. Chemaly RF, Ghosh S, Bodey GP, et al: Respiratory viral infections in adults with 
hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 85:278 -87, 2006  
 3. Shehata MA, Karim NA: Influenza vaccination in cancer patients undergoing systemic 
therapy. Clin Med Insights Oncol 8:57- 64, 2014  
 4. Engelhard D, Mohty B, de la Camara R, et al: European guidelines for prevention and 
management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of 
ECIL -4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transpl Infect 
Dis 15:219- 32, 2013  
 5. Kunisaki KM, Janoff EN: Influenza in immunosuppressed populations: a review of 
infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 9:493- 504, 2009  
 6. Pirofski LA, Casadevall A: Use of licensed vaccines for active immunization of the 
immunocompromised host. Clin Microbiol Rev 11:1- 26, 1998  
 7. Cooksley CD, Avritscher EB, Bekele BN, et al: Epidemiology and outcomes of serious 
influenza -related infections in the cancer population. Cancer 104:618- 28, 2005  
 8. Yousuf HM, Englund J, Couch R, et al: Influenza among hospitalized adults with 
leukemia. Clin Infect Dis 24:1095- 9, 1997  
 9. Ambati A, Boas LS, Ljungman P, et al: Evaluation of pretransplant influenza vaccination 
in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplant 50:858- 64, 2015  
 10. Natori Y, Humar A, Lipton J, et al: A pilot randomized trial of adjuvanted influenza 
vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 
52:1016- 1021, 2017  
 11. Howlander N, Noone A, Krapcho M, et al: SEER Cancer Statistics Review, 1975- 2011, 
National Cancer Institute. http://seer.cancer.gov/csr/1975_2011/
, 2014  
 12. Kumar SK, Dispenzieri A, Lacy MQ, et al: Continued improvement in survival in 
multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28:1122- 8, 2014  
 13. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66:7 -30, 2016  
 14. Walker BA, Wardell CP, Melchor L, et al: Intraclonal heterogeneity is a critical early 
event in the development of myeloma and precedes the development of clinical symptoms. Leukemia 28:384- 90, 2014  
 15. Rajkumar SV, Dimopoulos MA, Palumbo A, et al: International Myeloma Working 
Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538- 48, 2014  
 16. Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple myeloma 
and the impact of novel therapies. Blood 111:2516- 20, 2008  
 17. Brenner H, Gondos A, Pulte D: Recent major improvement in long- term survival of 
younger patients with multiple myeloma. Blood 111:2521- 6, 2008  
 18. Lavi N, Avivi I, Kra -Oz Z, et al: Community -acquired respiratory infections are common 
in patients with non- Hodgkin lymphoma and multiple myeloma. Support Care Cancer, 2018  
 19. Teh BW, Worth LJ, Harrison SJ, et al: Risks and burden of viral respiratory tract 
infections in patients with multiple myeloma in the era of immunomodulatory drugs and bortezomib: 
experience at an Australian Cancer Hospital. Support Care Cancer 23:1901- 6, 2015  
 20. Blimark C, Holmberg E, Mellqvist UH, et al: Multiple myeloma and infections: a 
population- based study on 9253 multiple myeloma patients. Haematologica 100:107- 13, 2015  
 21. Kristinsson SY, Tang M, Pfeiffer RM, et al: Monoclonal gammopathy of undetermined 
significance and risk of infections: a population- based study. Haematologica 97:854- 8, 2012  
   
 
42 
  22. Musto P, Carotenuto M: Vaccination against influenza in multiple myeloma. Br J 
Haematol 97:505 -6, 1997  
 23. Rapezzi D, Sticchi L, Racchi O, et al: Influenza vaccine in chronic lymphoproliferative 
disorders and multiple myeloma. Eur J Haematol 70:225- 30, 2003  
 24. Robertson JD, Nagesh K, Jowitt SN, et al: Immunogenicity of vaccination against 
influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple 
myeloma. Br J Cancer 82:1261- 5, 2000  
 25. Ljungman P, Nahi H, Linde A: Vaccination of patients with haematological malignancies 
with one or two doses of influenza vaccine: a randomised study. Br J Haematol 130:96- 8, 2005  
 26. Hahn M, Schnitzler P, Schweiger B, et al: Boost Vaccination Improves Humoral Immune 
Response Against Influenza Virus In Patients With Multiple Myeloma. Blood 122:3206- 3206, 2013  
 27. Branagan AR, Duffy E, Albrecht RA, et al: Clinical and Serologic Responses After a 
Two-dose Series of High- dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single- arm 
Trial. Clin Lymphoma Myeloma Leuk 17:296- 304 e2, 2017  
 28. Branagan A, Duffy E, Foster C, et al: Two Dose Series of High- Dose Influenza Vaccine 
Is Associated with Longer Duration of Serologic Immunity in Patients with Plasma Cell Disorders. Blood 
130:438- 438, 2017  
 29. Wrammert J, Koutsonanos D, Li GM, et al: Broadly cross -reactive antibodies dominate 
the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208:181-
93, 2011  
 30. Wrammert J, Smith K, Miller J, et al: Rapid cloning of high -affinity human monoclonal 
antibodies against influenza virus. Nature 453:667- 71, 2008  
 31. Ellebedy AH, Jackson KJ, Kissick HT, et al: Defining antigen- specific plasmablast and 
memory B cell subsets in human blood after viral infection or vaccination. Nat Immunol 17:1226- 34, 
2016  
 32. Tangye SG: Staying alive: regulation of plasma cell survival. Trends Immunol 32:595-
602, 2011  
 33. Yoshida T, Mei H, Dorner T, et al: Memory B and memory plasma cells. Immunol Rev 
237:117- 39, 2010  
 34. Hannoun C, Megas F, Piercy J: Immunogenicity and protective efficacy of influenza 
vaccination. Virus Res 103:133- 8, 2004  
 35. Hobson D, Curry RL, Beare AS, et al: The role of serum haemagglutination- inhibiting 
antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70:767-
77, 1972  
 36. Lasky T, Terracciano GJ, Magder L, et al: The Guillain -Barre syndrome and the 1992-
1993 and 1993- 1994 influenza vaccines. N Engl J Med 339:1797- 802, 1998  
 37. Haber P, DeStefano F, Angulo FJ, et al: Guillain- Barre syndrome following influenza 
vaccination. JAMA 292:2478- 81, 2004  
 38. De Wals P, Deceuninck G, Toth E, et al: Risk of Guillain- Barre syndrome following 
H1N1 influenza vaccination in Quebec. JAMA 308:175- 81, 2012  
 39. Juurlink DN, Stukel TA, Kwong J, et al: Guillain- Barre syndrome after influenza 
vaccination in adults: a population -based study. Arch Intern Med 166:2217- 21, 2006 
 40. Salmon DA, Proschan M, Forshee R, et al: Association between Guillain- Barre syndrome 
and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta -analysis. Lancet 
381:1461- 8, 2013  
 41. Polakowski LL, Sandhu SK, Martin DB, et al: Chart -confirmed guillain- barre syndrome 
after 2009 H1N1 influenza vaccination among the Medicare population, 2009- 2010. Am J Epidemiol 
178:962- 73, 2013  
 42. Dodd CN, Romio SA, Black S, et al: International collaboration to assess the risk of 
Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. Vaccine 31:4448- 58, 
2013  
   
 
43 
  43. Das R, Bar N, Ferreira M, et al: Early B cell changes predict autoimmunity following 
combination immune checkpoint blockade. J Clin Invest 128:715- 720, 2018  
 
 
 
  
   
 
44 
 APPENDIX A – PERFORMANCE STATUS  
 
Performance Status Criteria  
 
ECOG Performance Status Scale Karnofsky Performance Scale  
Grade  Descriptions  % Description  
0 Normal activity.  Fully active, 
able to carry on all pre -disease 
performance without restriction.  100 Normal, no complaints, no 
evidence of disease.  
90 Able to carry on normal 
activity; minor signs or 
symptoms of disease.  
1 Symptoms, but ambulatory.  
Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light 
housework, office work).  80 Normal activity with effort; 
some signs or symptoms of 
disease.  
70 Cares for self, unable to carry on normal activity or to do active work.  
2 In bed <50% of the time.  
Ambulatory and capable of all self-care, but unable to carry 
out any work activities.  Up and about more than 50% of 
waking hours.  60 Requires occasional assistance, 
but is able to care for most of 
his/her needs.  
50 Requires considerable 
assistance and frequent medical 
care.  
3 In bed >50% of the time.  
Capable of only limited self -
care, confined to bed or chair more than 50% of waking 
hours.  40 Disabled, requires special care 
and assistance.  
30 Severely disabled, 
hospitalization indicated.  
Death not imminent.  
4 100% bedridden.  Completely 
disabled.  Cannot carry on any self-care.  Totally confined to 
bed or chair.  20 Very sick, hospitalization 
indicated. Death not imminent.  
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead.  0 Dead.  
  